dabigatran우선순위 중간ICSR 검토기타
LITERATURE DETAIL · PMID 42438486
A first-in-human study evaluating safety, PK, and PD of a novel universal anticoagulant reversal agent, OKL-1111.
A first-in-human study evaluating safety, PK, and PD of a novel universal anticoagulant reversal agent, OKL-1111.
- 저자
- Edwin Spaans, Denisa Wilkes, Maxime Schreurs, Julien Beyrath, Jules A A C Heuberger, Alex Zwiers
- 저널
- Blood vessels, thrombosis & hemostasis
- 공개일
- 2026 Aug
- 연구 유형
- 기타
- DOI
- 10.1016/j.bvth.2026.100176
문헌 요약
OKL-1111 is a small-molecule γ-cyclodextrin universal reversal agent for anticoagulants and platelet inhibitors that was being developed to significantly shorten time to treatment for intracerebral hemorrhage. Part A of this single-center, randomized, placebo-controlled, double-blind, single-ascending-dose, alternating-group, partial crossover trial evalu…
PV 검토 포인트
개별 증례 가능성과 중대성, 예상성 및 중복 여부를 우선 검토합니다.